Pharmaceuticals in Scandinavia
Summary
Pharmaceuticals in Scandinavia industry profile provides top-line qualitative and quantitative summary information including: market size (value 2019-24, and forecast to 2029). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Key Highlights
Pharmaceuticals in Scandinavia industry profile provides top-line qualitative and quantitative summary information including: market size (value 2019-24, and forecast to 2029). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Key Highlights
- The pharmaceutical market includes sales of both prescriptions and over-the-counter (OTC) drugs. The market scope does not cover consumer healthcare and animal health products.
- The Scandinavian pharmaceuticals market recorded revenues of $17.5 billion in 2024, representing a compound annual growth rate (CAGR) of 3.5% between 2019 and 2024.
- The central nervous system drugs segment accounted for the market's largest proportion in 2024, with total revenues of $2.3 billion, equivalent to 12.9% of the market's overall value.
- Sweden dominated the Scandinavian pharmaceuticals market in 2024, accounting for the largest share of 42.0%, followed by Norway, capturing a share of 30.0%.
- Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the pharmaceuticals market in Scandinavia
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the pharmaceuticals market in Scandinavia
- Leading company profiles reveal details of key pharmaceuticals market players? global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the Scandinavia pharmaceuticals market with five year forecasts
- What was the size of the Scandinavia pharmaceuticals market by value in 2024?
- What will be the size of the Scandinavia pharmaceuticals market in 2029?
- What factors are affecting the strength of competition in the Scandinavia pharmaceuticals market?
- How has the market performed over the last five years?
- What are the main segments that make up Scandinavia's pharmaceuticals market?
1 EXECUTIVE SUMMARY
1.1. Market value
1.2. Market value forecast
1.3. Category segmentation
1.4. Geography segmentation
1.5. Market rivalry
1.6. Competitive landscape
2 MARKET OVERVIEW
2.1. Market definition
2.2. Market analysis
3 MARKET DATA
3.1. Market value
4 MARKET SEGMENTATION
4.1. Category segmentation
4.2. Geography segmentation
5 MARKET OUTLOOK
5.1. Market value forecast
6 FIVE FORCES ANALYSIS
6.1. Summary
6.2. Buyer power
6.3. Supplier power
6.4. New entrants
6.5. Threat of substitutes
6.6. Degree of rivalry
7 COMPETITIVE LANDSCAPE
7.1. Who are the leading players?
7.2. What are the strategies of the leading players?
7.3. What are the most recent market developments?
8 COMPANY PROFILES
8.1. F. Hoffmann-La Roche Ltd
8.2. H. Lundbeck AS
8.3. Novo Nordisk AS
9 MACROECONOMIC INDICATORS
9.1. Country data
10 APPENDIX
10.1. Methodology
10.2. Industry associations
10.3. Related MarketLine research
10.4. About MarketLine
1.1. Market value
1.2. Market value forecast
1.3. Category segmentation
1.4. Geography segmentation
1.5. Market rivalry
1.6. Competitive landscape
2 MARKET OVERVIEW
2.1. Market definition
2.2. Market analysis
3 MARKET DATA
3.1. Market value
4 MARKET SEGMENTATION
4.1. Category segmentation
4.2. Geography segmentation
5 MARKET OUTLOOK
5.1. Market value forecast
6 FIVE FORCES ANALYSIS
6.1. Summary
6.2. Buyer power
6.3. Supplier power
6.4. New entrants
6.5. Threat of substitutes
6.6. Degree of rivalry
7 COMPETITIVE LANDSCAPE
7.1. Who are the leading players?
7.2. What are the strategies of the leading players?
7.3. What are the most recent market developments?
8 COMPANY PROFILES
8.1. F. Hoffmann-La Roche Ltd
8.2. H. Lundbeck AS
8.3. Novo Nordisk AS
9 MACROECONOMIC INDICATORS
9.1. Country data
10 APPENDIX
10.1. Methodology
10.2. Industry associations
10.3. Related MarketLine research
10.4. About MarketLine
LIST OF TABLES
Table 1: Scandinavia pharmaceuticals market value: $ million, 2019-24
Table 2: Scandinavia pharmaceuticals market category segmentation: % share, by value, 2019-24
Table 3: Scandinavia pharmaceuticals market category segmentation: $ million, 2019-24
Table 4: Scandinavia pharmaceuticals market geography segmentation: $ million, 2024
Table 5: Scandinavia pharmaceuticals market value forecast: $ million, 2024-29
Table 6: F. Hoffmann-La Roche Ltd: Key Facts
Table 7: F. Hoffmann-La Roche Ltd: Key Employees
Table 8: H. Lundbeck AS: Key Facts
Table 9: H. Lundbeck AS: Annual Financial Ratios
Table 10: H. Lundbeck AS: Key Employees
Table 11: Novo Nordisk AS: Key Facts
Table 12: Novo Nordisk AS: Annual Financial Ratios
Table 13: Novo Nordisk AS: Key Employees
Table 14: Scandinavia Exchange Rate, 2019-24
Table 1: Scandinavia pharmaceuticals market value: $ million, 2019-24
Table 2: Scandinavia pharmaceuticals market category segmentation: % share, by value, 2019-24
Table 3: Scandinavia pharmaceuticals market category segmentation: $ million, 2019-24
Table 4: Scandinavia pharmaceuticals market geography segmentation: $ million, 2024
Table 5: Scandinavia pharmaceuticals market value forecast: $ million, 2024-29
Table 6: F. Hoffmann-La Roche Ltd: Key Facts
Table 7: F. Hoffmann-La Roche Ltd: Key Employees
Table 8: H. Lundbeck AS: Key Facts
Table 9: H. Lundbeck AS: Annual Financial Ratios
Table 10: H. Lundbeck AS: Key Employees
Table 11: Novo Nordisk AS: Key Facts
Table 12: Novo Nordisk AS: Annual Financial Ratios
Table 13: Novo Nordisk AS: Key Employees
Table 14: Scandinavia Exchange Rate, 2019-24
LIST OF FIGURES
Figure 1: Scandinavia pharmaceuticals market value: $ million, 2019-24
Figure 2: Scandinavia pharmaceuticals market category segmentation: $ million, 2019-24
Figure 3: Scandinavia pharmaceuticals market geography segmentation: % share, by value, 2024
Figure 4: Scandinavia pharmaceuticals market value forecast: $ million, 2024-29
Figure 5: Forces driving competition in the pharmaceuticals market in Scandinavia, 2024
Figure 6: Drivers of buyer power in the pharmaceuticals market in Scandinavia, 2024
Figure 7: Drivers of supplier power in the pharmaceuticals market in Scandinavia, 2024
Figure 8: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Scandinavia, 2024
Figure 9: Factors influencing the threat of substitutes in the pharmaceuticals market in Scandinavia, 2024
Figure 10: Drivers of degree of rivalry in the pharmaceuticals market in Scandinavia, 2024
Figure 1: Scandinavia pharmaceuticals market value: $ million, 2019-24
Figure 2: Scandinavia pharmaceuticals market category segmentation: $ million, 2019-24
Figure 3: Scandinavia pharmaceuticals market geography segmentation: % share, by value, 2024
Figure 4: Scandinavia pharmaceuticals market value forecast: $ million, 2024-29
Figure 5: Forces driving competition in the pharmaceuticals market in Scandinavia, 2024
Figure 6: Drivers of buyer power in the pharmaceuticals market in Scandinavia, 2024
Figure 7: Drivers of supplier power in the pharmaceuticals market in Scandinavia, 2024
Figure 8: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Scandinavia, 2024
Figure 9: Factors influencing the threat of substitutes in the pharmaceuticals market in Scandinavia, 2024
Figure 10: Drivers of degree of rivalry in the pharmaceuticals market in Scandinavia, 2024
